Revvity (RVTY) Q4 2025 earnings summary

Executive summary

• Q4 2025 revenue reached $772 million, up 6% year-over-year with 4% organic growth, and adjusted EPS was $1.70, up 20% year-over-year, closing the year above initial guidance despite market and policy headwinds.

• Full-year 2025 revenue totaled $2.86 billion, up 4% year-over-year, with adjusted EPS at $5.06, up from $4.90 in 2024, and 3% organic growth, demonstrating resilience and execution.

• Diagnostics and Reproductive Health segments outperformed, with Diagnostics leading Q4 at 7% organic growth and Immunodiagnostics and Reproductive Health both posting strong results.

• Over $800 million in share repurchases in 2025, reducing share count by 8.5 million; total repurchases since mid-2023 exceed $1.5 billion.

• Launched Signals Xynthetica, an AI Models-as-a-Service platform, and announced collaboration with Lilly's TuneLab.

Financial highlights

• Q4 2025 revenue: $772 million, 4% organic growth, 6% total growth; full year: $2.86 billion, 3% organic growth, 4% total growth.

• Adjusted operating margin Q4: 29.7% (down 60 bps YoY); full year: 27.1% (down 120 bps YoY).

• Adjusted EPS Q4: $1.70, up 20% YoY; full year: $5.06, up 3% YoY.

• Free cash flow Q4: $162 million (84% conversion); full year: $515 million (87% conversion).

• Net debt to adjusted EBITDA: 2.7x; all debt fixed rate, 2.6% average interest, 6-year maturity.

Outlook and guidance

• 2026 revenue guidance: $2.96–$2.99 billion, 2–3% organic growth, 1% FX tailwind, and 0.75% M&A contribution.

• Adjusted operating margin guidance: 28% for 2026, up from 27.1% in 2025.

• Adjusted EPS guidance for 2026: $5.35–$5.45, high single-digit growth.

• Adjusted tax rate for 2026: 18%, up from 14.5% in 2025; net interest expense expected at $95 million.

• Diluted average share count expected at 112 million for 2026.